A 5-year study of systemic reactions using both shared and patient-specific vaccines.

The safety of shared specific vaccines (SSVs) has been questioned by some experts. The purpose of this study was to evaluate the safety of SSVs. Details of systemic allergic reactions after subcutaneous immunotherapy injections were captured on a standardized form from July 2005 to July 2010. Patient records were evaluated for factors that might be associated with increased rate of systemic reactions and, in addition, were examined for any errors. Systemic reaction rates (SRRs) using a combination of shared and patient-specific vaccines (PSVs) were similar to previously reported studies (0.23 reactions per 100 shots). There were no systemic reactions resulting from errors where the incorrect shared allergen was administered, but we did note one reaction after an erroneously administered PSV. There were two dosage errors associated with both shared and patient-specific immunotherapy. Most reactions were mild to moderate (World Allergy Organization grade, 1 or 2). Severe reactions with 911 activations were noted in six patients. Thirty percent of reactions occurred out of the office and the average time to reaction was 48 minutes. Epinephrine was administered in only 60% of patients. Epicutaneous reactivity to mites, cats, dogs, and pollen but not mold occurred significantly more in reactors. Differences in SRRs were encountered between satellite offices. Using a combination of SSV and PSV, SRRs were similar to previously reported studies; moreover, no systemic reactions occurred where a SSV was erroneously administered. SRR surveillance is a useful safety tool.

Radiocontrast media allergic reactions and interventional pain practice--a review.

BACKGROUND: Millions of interventional pain procedures are performed each year in the United States. Interventional pain physicians commonly administer radiocontrast media (RCM) under fluoroscopy for these procedures. However, RCM can cause various types of hypersensitivity or allergic type reactions, in an acute or delayed fashion. Furthermore, some patients report a prior history of hypersensitivity reactions to RCM when presenting to the interventional pain clinic. Both scenarios present challenges to the interventional pain physician. OBJECTIVE: To describe the various types of hypersensitivity reactions to RCM, as well as strategies to prevent and manage these reactions, within the context of interventional pain practice. METHOD: A review of the literature from 1975 through 2011 regarding allergic type reactions to RCM, as well as iodine, and shellfish allergy, was undertaken in an effort to review and develop recommendations on managing these patients presenting to the interventional pain clinic. Keywords used in the literature search were: radiocontrast media, contrast allergy, contrast reaction, iodine allergy, shellfish allergy, and fluoroscopy. The included articles were concerned with the basic or clinical science of contrast allergy, including the physiology, epidemiology, diagnosis, and management of such reactions. Meta-analysis, review articles, and case reports addressing contrast media reactions were also included. Articles which discussed contrast media reactions in a peripheral fashion were excluded. RESULTS: In reviewing the literature, it is apparent that the mechanisms and pathophysiology of RCM hypersensitivity reactions are still being characterized, which should soon lead to improved screenings, as well as prevention and treatment strategies. Many common themes are described throughout the literature regarding patient risk factors, testing, prevention,diagnosis, and treatment of RCM allergic-type reactions. LIMITATIONS: The current review did not perform a meta-analysis of the available data, as most of the available articles were trials that were randomly controlled. Therefore, the conclusions of the present article are general, and qualitative in nature. CONCLUSION: Although the mechanisms of various RCM allergic-type reactions are not entirely understood, the interventional pain physician should have a basic understanding of patient risk factors, prevention, diagnosis, and treatment of these reactions. The current review allowed for prevention and treatment strategies for managing patients with RCM hypersensitivity reactions.

Intravenous gammaglobulin treatment in HIV-1 infection.

The two main indications for the use of intravenous gammaglobulin--antibody replacement therapy and immunomodulation--are pertinent only for a few scenarios in HIV-1 infection. The role of gammaglobulin in the treatment of HIV-1 infection has changed significantly with the introduction of highly active antiretroviral therapy. Antiretroviral drugs have not only controlled the progression of disease but also had far-reaching effects on HIV-1-induced immunologic aberrations. Complete or partial immunologic reconstitution and prevention of immunologic damage have been the hallmarks of success for highly active antiretroviral therapy. This article addresses the use of gammaglobulin before and after the era of effective antiretroviral therapies.

Subspecialty evaluation of chronically ill hospitalized patients with suspected immune defects.

BACKGROUND: The diagnosis of primary immunodeficiency is suggested by recurrent or unusual infections and inflammatory and autoimmune conditions. Because the diversity of immune defects and clinical presentations poses a diagnostic challenge in hospital populations, a computer algorithm was devised to help identify patients. OBJECTIVE: To assess use of pertinent subspecialty clinics by patients with clinical features of immunodeficiency. METHODS: Using a validated algorithm based on International Classification of Diseases, Ninth Revision (ICD-9), codes applied to The Mount Sinai Hospital billing records, we investigated hospitalized patients, 60 years or younger, who had been diagnosed as having conditions associated with immunodeficiency, excluding those with confounding medical conditions. Immunodeficiency-related disease codes were given a weighted score based on relative severity and expressed as a sum for admissions between January 1, 1999, and December 31, 2003. Demographic features, subspecialty care, and clinic attendance were determined. RESULTS: The 296 computer-identified patients with illnesses characteristic of immunodeficiency were 35.8% Hispanic, 27.0% African American, and 21.6% white; their median age was 13.3 years. Patients were hospitalized 1,261 times, or a median of 4.2 times each (range, 1-42 times), and had 5,700 diagnoses. Of the patients, 75.0% received primary care at The Mount Sinai Hospital. Although the most common diagnosis was pneumonia (n = 243), 45% of patients never received allergy/immunology or pulmonary subspecialty care. CONCLUSION: Despite receiving primary medical care at the same hospital, many frequently hospitalized subjects with features of immunodeficiency do not receive medical care in appropriate subspecialty clinics.